Drug or treatment

CART clinical trials

• 38Clinical trials
• 11Countries

Newest trials

All recruiting trials (38)

• Isometric wall squat exercise to lower blood pressure in adults with hypertension

  We’re testing whether doing isometric wall squats at home for 12 weeks can help lower 24-hour blood pressure in adults with essential hypertension.

  Recruiting Korea University Guro Hospital · Seoul, Seoul · NCT07868822

• Ring-style blood pressure bracelet test compared with 24-hour monitoring in people with HFrEF

  A ring-type blood pressure device is being tested to see if its 24-hour readings match those from standard ambulatory monitoring in adults with heart failure and reduced ejection fraction.

  Recruiting Keimyung University Dongsan Medical Center · Daegu · NCT07626879

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

• CART BP Pro-guided management for people with uncontrolled high blood pressure

  This project will see if using the wearable CART BP Pro ring to guide treatment helps lower blood pressure more than usual office-based care for adults in Korea whose blood pressure is not controlled.

  Recruiting at 3 sites Korea University Anam Hospital · Ansan and 2 other locations · NCT07465549

• CART123 Cells With or Without Ruxolitinib for Relapsed/Refractory AML

  This trial tests CART123 cells alone or with ruxolitinib to see if they help kids and young adults with relapsed or treatment‑resistant AML.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07464951

• Autologous CD45 base-edited stem cells plus CART-45 cells for relapsed or refractory hematologic cancers

  This phase 1 study tests whether a patient’s own edited stem cells and CART-45 cells can be given safely to treat relapsed or refractory B-cell and T-cell lymphomas and Hodgkin lymphoma.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07451054

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

• Monitoring CAR‑BCMA immune cells in multiple myeloma

  This project will test whether tracking CAR‑BCMA cells and related immune markers in blood and bone marrow can help predict which multiple myeloma patients respond to CAR‑T therapy.

  Recruiting Poitiers University Hospital · Poitiers · NCT07342179

• Naive HBI0101 CAR-T therapy for adults with relapsed or refractory multiple myeloma.

  This trial will try Naive HBI0101 CAR-T cell therapy to see if it is safe and helps adults whose multiple myeloma has come back or not responded to prior treatments.

  Recruiting Phase 1 Hadassah Medical Organization · Jerusalem · NCT07333430

• MB-CART19.1 CAR-T for adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma.

  This study will try a single infusion of MB-CART19.1 CAR-T cells in adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma to see if it can reduce disease and is safe.

  Recruiting Phase 2 King Hussein Cancer Center · Amman · NCT07271121

• Monocytes and CAR‑T Cell Response in Multiple Myeloma

  This project will test whether the number and type of monocytes before and after CAR‑T cell therapy help predict how well CAR‑T works for adults with multiple myeloma.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07180992

• BCMA CAR-T with or without autologous stem cell transplant for young multiple myeloma patients

  This will test whether BCMA-directed CAR-T cell therapy, given with or without autologous stem cell transplant (ASCT), helps young women (ages 18–55) with newly diagnosed multiple myeloma.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07169500

• supCD7 CAR-T for relapsed or refractory CD7-positive T-cell leukemia/lymphoma and AML

  This treatment will try supCD7 CAR‑T cells to see if they help adults whose CD7‑positive T‑cell leukemia/lymphoma or AML has come back or not responded to prior therapy.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07153068

• Universal CD7 CAR-T therapy for relapsed or refractory CD7-positive blood cancers

  This trial will test whether universal CD7 CAR-T cells can safely reduce disease in adults whose CD7-positive AML or T-ALL/LBL has relapsed or stopped responding to prior treatments.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07109518

• CD180 CAR-T for relapsed or refractory CD180-positive blood cancers

  This trial will test whether an intravenous CD180 CAR‑T cell therapy can help adults with relapsed or refractory CD180‑positive AML or B‑ALL/LBL.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07106749

• Autologous stem cell transplant combined with CD7 CAR‑T for CD7‑positive T‑cell lymphoma

  This will test whether giving a patient's own stem cell transplant together with CD7‑targeted CAR‑T cells can safely and better treat adults with CD7‑positive T‑cell lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07106723

• HBI0101 CAR-T for refractory B‑cell autoimmune rheumatic diseases

  This will test a single infusion of HBI0101 CAR‑T cells in adults with severe, treatment‑resistant B‑cell autoimmune diseases such as SLE, systemic sclerosis, idiopathic inflammatory myopathy, rheumatoid arthritis, or primary progressive MS.

  Recruiting Phase 1 Hadassah Medical Organization · Jerusalem · NCT07085676

• BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases

  This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT07022197

• HBI0101 CAR-T therapy for multiple myeloma and light-chain amyloidosis

  This study is testing a new CAR-T therapy called HBI0101 to see if it can help people with relapsed or hard-to-treat multiple myeloma and light-chain amyloidosis feel better.

  Recruiting Phase 2 Hadassah Medical Organization · Jerusalem · NCT06971380

• Umbilical cord blood CD19-BCMA CAR T cell treatment for refractory lupus nephritis, systemic sclerosis, and Sjögren's with pulmonary hypertension

  This treatment will try umbilical cord blood–derived CD19‑BCMA CAR T cells in people with refractory lupus nephritis, systemic sclerosis, or primary Sjögren's syndrome with pulmonary hypertension who have not responded to standard therapies.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06947473

• CD19-BCMA CAR T cell therapy for difficult-to-treat autoimmune diseases

  This study is testing a new CAR T cell therapy to see if it can help people with tough autoimmune diseases like lupus nephritis, systemic sclerosis, and Sjogren's syndrome who haven't found relief with regular treatments.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, China,Beijing · NCT06947460

• Phase I CAR T-cell therapy for relapsed or refractory acute lymphoblastic leukemia in children, adolescents, and young adults

  This phase I study will test two CAR T-cell approaches to see if they are safe and feasible for children and young adults with relapsed or refractory B-ALL or T-ALL.

  Recruiting Phase 1 Instituto de Investigación Hospital Universitario La Paz · Madrid, Madrid · NCT06709469

• Combining stem cell transplantation with CD19-CART for treating high-risk leukemia in adults

  This study is testing a new treatment that combines stem cell transplant with a special type of immune therapy to see if it helps adults with high-risk leukemia feel better and stay in remission.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06608342

• WU-CART-007 anti-CD7 CAR-T for relapsed or MRD-positive T-cell ALL and lymphoblastic lymphoma

  This trial will try WU-CART-007, an off-the-shelf anti-CD7 CAR-T therapy, in people with relapsed/refractory or MRD-positive T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma to see if it produces MRD-negative remissions.

  Recruiting at 18 sites Phase 2 Allotera Therapeutics · Duarte, California and 17 other locations · NCT06514794

• Validating the CART BP ring cuffless blood pressure monitor

  This study will test whether the CART BP ring gives blood pressure readings that match the standard cuff method in adults with suspected high or low blood pressure.

  Recruiting Sky Labs · Seoul · NCT06513975

• Zamtocabtagene autoleucel (MB-CART2019.1) for children and teens with relapsed or refractory mature B‑cell cancers

  This study will try one fresh infusion of MB-CART2019.1, a tandem CD20‑CD19 CAR‑T treatment, in children and adolescents (6 months to under 18 years) whose mature B‑cell cancers have come back or not responded to prior therapy.

  Recruiting at 2 sites Phase 2 Miltenyi Biomedicine GmbH · Paris, Boulevard Sérurier 48 and 4 other locations · NCT06508931

• Using modified T cells to treat certain solid tumors in children and young adults

  This study is testing a new treatment using modified T cells to see if it can help children and young adults with tough-to-treat solid tumors.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06500819

• Cell therapy combined with enzalutamide for advanced prostate cancer

  This study is testing a new combination of cell therapy and a medication called enzalutamide to see if it helps people with advanced prostate cancer live better and longer.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06236139

• Combining CC-99282 with Rituximab for Non-Hodgkin's Lymphoma Treatment

  This study is testing a new combination of a pill called CC-99282 and an infusion called rituximab to see if it helps people with non-Hodgkin's lymphoma who didn't respond well to previous treatments.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06209619

• Testing a new CAR-T therapy for multiple myeloma

  This study tests a new CAR-T therapy to see if it can help people with tough-to-treat multiple myeloma feel better after other treatments haven't worked.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06185751

• Talquetamab treatment for multiple myeloma after BCMA CAR T-cell therapy

  This study is testing if talquetamab can help people with multiple myeloma who haven't improved after receiving BCMA CAR T-cell therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06066346

• Combining two CAR T cell therapies for treating advanced B-ALL in children

  This study is testing if giving two types of CAR T cell therapies together can help children and young adults with advanced B-cell leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05674175

• Using modified T cells to treat advanced prostate cancer

  This study is testing a new treatment using modified immune cells to see if it can help people with advanced prostate cancer feel better and tolerate the therapy.

  Recruiting Phase 1 Nova Therapeutics LLC · Beijing · NCT05656573

• Evaluating blood tests to monitor recovery after CAR T-cell therapy in young patients with leukemia

  This study is testing new blood tests to help doctors keep an eye on young patients with leukemia after their CAR T-cell therapy to see who might need extra treatment and who can stay healthy without it.

  Recruiting at 8 sites National Institutes of Health Clinical Center (CC) · Los Angeles, California and 7 other locations · NCT05621291

• Investigating a new cell therapy for pemphigus vulgaris

  This study is testing a new cell therapy for people with pemphigus vulgaris who haven't found relief with standard treatments to see if it can help them feel better.

  Recruiting at 10 sites Phase 1/2 Cabaletta Bio · Redwood City, California and 12 other locations · NCT04422912

• T Cell Therapy for Chemotherapy Refractory Multiple Myeloma

  This study is testing a new treatment using specially modified immune cells to help adults with hard-to-treat multiple myeloma fight their cancer.

  Recruiting Phase 1/2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT03196414

• CD30-targeted CAR T-cell therapy for relapsed and refractory lymphomas

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Hodgkin's and Non-Hodgkin's lymphoma.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT02259556

Quick answers

How many clinical trials of CART are recruiting right now?

38, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in United States (14 trials), China (12 trials), South Korea (4 trials), France (3 trials), Israel (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 14, Phase 1/2: 10, Phase 2: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →